Table 2.
Risk/protective factors for disease progression in patients with gastroenteropancreatic neuroendocrine tumors on SSA monotherapy
| Parameter | Univariate | Multivariate a | ||
|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | |
| Gender (male vs. female) | 1.35 (0.66–2.77) | .412 | ||
| Age (increasing) | 1.07 (0.75–1.53) | .695 | ||
| Site of primary tumor (GI vs. pancreas) | 0.76 (0.34–1.70) | .499 | ||
| Grade (1 vs. 2) | 0.27 (0.12–0.61) | .002 | ||
| Ki67 (≤5% vs. >5%) | 0.37 (0.17–0.81) | .010 | ||
| Mitotic count (<2 vs. ≥2 per 10 HPFs) | 1.17 (1.04–1.31) | .007 | NA | |
| Germline mutation (yes vs. no) | 1.63 (0.49–5.47) | .428 | ||
| Functioning tumor (yes vs. no) | 0.64 (0.31–1.32) | .220 | ||
| Chromogranin A (normal vs. elevated) | 0.91 (0.42–1.97) | .805 | ||
| Urine 5‐HIAA (normal vs. elevated) | 1.32 (0.43–4.06) | .627 | NA | |
| SSA naïve (yes vs. no) | 2.33 (1.06–5.12) | .034 | ||
| SUVmax (<18.35 vs. ≥18.35) | 4.15 (1.88–9.15) | <.001 | 6.85 (2.10–22.34) | .001 |
a
Only statistically significant (p < .05) results are reported for multivariate analysis.
Abbreviations: 5‐HIAA, 5‐hydroxyinidoleacetic acid; CI, confidence interval; GI, gastrointestinal; HPF, high‐power field; HR, hazard ratio; NA, not applicable (not included in multivariate analysis because of inconsistent reporting); SSA, somatostatin analog; SUVmax, maximum standardized uptake value.